Barclays PLC Acquires 66,550 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Barclays PLC increased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 113.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 125,397 shares of the company’s stock after acquiring an additional 66,550 shares during the quarter. Barclays PLC’s holdings in Viridian Therapeutics were worth $2,851,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of VRDN. Arizona State Retirement System grew its position in Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after purchasing an additional 1,688 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Viridian Therapeutics by 17.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,997 shares of the company’s stock worth $318,000 after buying an additional 2,036 shares in the last quarter. AlphaCentric Advisors LLC increased its stake in Viridian Therapeutics by 20.0% during the third quarter. AlphaCentric Advisors LLC now owns 15,000 shares of the company’s stock valued at $341,000 after acquiring an additional 2,500 shares during the period. DCF Advisers LLC lifted its position in shares of Viridian Therapeutics by 22.4% in the 2nd quarter. DCF Advisers LLC now owns 17,750 shares of the company’s stock worth $231,000 after acquiring an additional 3,250 shares during the period. Finally, Quest Partners LLC grew its holdings in shares of Viridian Therapeutics by 344.0% during the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock worth $79,000 after purchasing an additional 4,692 shares in the last quarter.

Insider Activity

In other news, CEO Stephen F. Mahoney purchased 21,400 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the acquisition, the chief executive officer now directly owns 21,400 shares in the company, valued at approximately $499,262. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Thomas W. Beetham acquired 5,000 shares of the company’s stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of $23.41 per share, with a total value of $117,050.00. Following the completion of the acquisition, the chief operating officer now directly owns 6,000 shares in the company, valued at approximately $140,460. The trade was a 500.00 % increase in their position. The disclosure for this purchase can be found here. 0.65% of the stock is owned by insiders.

Viridian Therapeutics Price Performance

Viridian Therapeutics stock opened at $19.31 on Wednesday. The business’s fifty day moving average is $21.64 and its two-hundred day moving average is $18.25. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The firm has a market cap of $1.53 billion, a P/E ratio of -4.48 and a beta of 1.04. Viridian Therapeutics, Inc. has a 52 week low of $11.40 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.08 million. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on VRDN. BTIG Research raised their target price on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, September 26th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a research note on Monday, November 25th. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. Royal Bank of Canada lifted their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. Finally, Wells Fargo & Company reissued an “equal weight” rating and issued a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $35.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.